Compare Quest Diagnostics Inc (DGX) vs Intel Corp (INTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Intel Corp — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while Intel Corp trades at $100.65 (market cap $492.85B). The key difference: Intel Corp is far larger — about 18.8× Quest Diagnostics Inc's market cap, and Intel Corp pays the higher dividend (2.24%). Which is the better fit depends on your goals.
| DGX | INTC | |
|---|---|---|
Market Cap | $26.21B | $492.85B |
Sector | Health | Technology |
52-Week High | $238.50 | $140.94 |
52-Week Low | $173.49 | $21.81 |
Enterprise Value | $31.97B | $513.66B |
Dividend Yield | 1.45% | 2.24% |
Volume | — | 43,552,012 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Intel (INTC) trades at $102.74, up 5.35% today, with a bullish technical signal from moving averages but mixed oscillators. Recent earnings beats in Q1 and Q2 2026 highlight improving operational performance, though net income remains negative. The company is raising $20 billion via a stock offering to fund AI and foundry expansion, driving investor focus on growth prospects amid margin challenges.
Outlook: Intel's revenue growth and strategic investments in AI present upside potential, but shareholder dilution from the equity raise and persistent negative margins pose risks. Analyst consensus is mixed with a $116.67 price target, suggesting cautious optimism for the turnaround story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →
